How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

632 results for

Wart Immune Therapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Typing of Human Papilloma Virus (HPV) From Female Genital Warts

Hospital Over a One Year Period, Evaluated by HIV Status, Psychological Impact and Costs to the Health Care System Study Start Date : April 2010 Actual Primary Completion Date : December 2011 Actual Study Completion Date : August 2012 Resource links provided by the National Library of Medicine related topics: Groups and Cohorts Go to Group/Cohort Intervention/treatment Genital Warts All female patients with Genital Warts presenting to Groote Schuur Hospital Procedure: Medical / Surgical Treatment All (...) will be determined with patient consent, treatment modalities will be documented as will the outcome of treatment over a 6 month's period. Risk factors for recurrence or failure of treatment will be analysed as will the costs of treating women with genital warts. Condition or disease Intervention/treatment Genital Warts Human Papilloma Virus Procedure: Medical / Surgical Treatment Detailed Description: Genital Human Papillomavirus (HPV) infection is the most common sexually transmitted viral disease in the world

2010 Clinical Trials

142. A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin

With Combined Liquid Nitrogen Cryotherapy and Topically Applied Cantharidin Study Start Date : June 2007 Actual Primary Completion Date : June 2008 Actual Study Completion Date : September 2008 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Liquid nitrogen and canthardin Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterwards. Drug: Liquid nitrogen and cantharidin Liquid (...) , 2010 Sponsor: North Idaho Dermatology Information provided by: North Idaho Dermatology Study Details Study Description Go to Brief Summary: The purpose of the study was to see if liquid nitrogen, a commonly used treatment for warts, is more effective if it is used alone, or if it is more effective if combined with cantharidin, a topical treatment also commonly used for warts (verruca vulgaris). Condition or disease Intervention/treatment Phase Verruca Vulgaris Drug: Liquid nitrogen and cantharidin

2010 Clinical Trials

143. Vaginal Cancer Treatment (PDQ®): Health Professional Version

or recurrent disease, or when the risk of surgery is high.[ ] The entire vaginal mucosa is usually treated.[ ] Imiquimod cream 5%, an immune stimulant used to treat genital warts, is an additional topical therapy that has a reported complete clinical response rate of 50% to 86% in small case series of patients with multifocal high-grade HPV-associated VaIN 2 and VaIN 3.[ ] However, it is investigational, and it may have only short-lived efficacy.[ ] Women with VaIN 1 can usually be observed carefully (...) . Regional lymph nodes are included in the radiation portal. When used alone, EBRT involves a tumor dose of 65 Gy to 70 Gy, using shrinking fields, delivered within 6 to 7 weeks. Intracavitary brachytherapy provides insufficient dose penetration for locally advanced tumors, so interstitial brachytherapy is used if brachytherapy is given.[ , ] For patients with stage IVb or recurrent disease that cannot be managed with local treatments, current therapy is inadequate. No established anticancer drugs have

2017 PDQ - NCI's Comprehensive Cancer Database

144. Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®): Health Professional Version

Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®): Health Professional Version Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer (...) . Therapy-related myeloid neoplasms. AML, NOS: - AML with minimal differentiation. - AML without maturation. - AML with maturation. - Acute myelomonocytic leukemia. - Acute monoblastic/monocytic leukemia. - Pure erythroid leukemia. - Acute megakaryoblastic leukemia. - Acute basophilic leukemia. - Acute panmyelosis with myelofibrosis. Myeloid sarcoma. Myeloid proliferations related to Down syndrome: - Transient abnormal myelopoiesis (TAM). - Myeloid leukemia associated with Down syndrome. 2016 WHO

2017 PDQ - NCI's Comprehensive Cancer Database

145. Anal Cancer Prevention (PDQ®): Health Professional Version

) for men. Increased risk for both men and women has been observed with a history of anal warts and certain other sexually transmitted diseases.[ ] Chronic immunosuppressive states other than HIV infection Chronic immunosuppression in general is thought to increase risk of anal cancer because of its impact on the ability to clear HPV infection.[ ] Organ transplant recipients are at elevated risk of anal cancer because immunosuppressant medications are used to prevent organ rejection. Three large (...) Anal Cancer Prevention (PDQ®): Health Professional Version Anal Cancer Prevention (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): ; 2002

2017 PDQ - NCI's Comprehensive Cancer Database

146. Cervical Cancer Prevention (PDQ®): Health Professional Version

against HPV infection offer a primary prevention strategy for cervical cancer. A quadrivalent (HPV-6, -11, -16, and -18) vaccine using a late protein L1 construct to induce antibody-mediated immunity was approved for use by the U.S. Food and Drug Administration in 2006; a bivalent (HPV-16, -18) vaccine was approved in 2009; and a vaccine targeting nine HPV types was approved in 2014. Vaccination during pregnancy has not been associated with adverse pregnancy outcomes.[ ] Persistent infection (...) significant magnitude of protection of 0.65 (95% CI, 0.43–0.96; P < .03) among unvaccinated women, suggesting herd immunity (protection of unvaccinated individuals).[ ] These data strengthen previous results that suggest herd immunity in this population manifested as a reduction in genital warts among heterosexual men, a group that includes sexual partners of vaccinated women.[ ] Data also suggest cross protection against carcinogenic types that are not directly targeted by the quadrivalent vaccine

2017 PDQ - NCI's Comprehensive Cancer Database

147. Cervical cancer and HPV

of hormone replacement therapy for 6 weeks. Refer premenopausal women to gynaecology or genitourinary medicine clinic, who have: Persistent intermenstrual bleeding, post-coital bleeding, or blood-stained vaginal discharge, and: Polyp, ectropion, cervicitis, or warts. Infection has been excluded or infection had been treated, but the bleeding has continued for 6–8 weeks post treatment. Consider urgent referral (within 2 weeks) for women with persistent intermenstrual bleeding and a negative pelvic (...) be arranged for all women in whom there appears to be a visible suspicion of cervical cancer, or an abnormal cervical cytology sample. An urgent referral to gynaecology (within 2 weeks) should be arranged for postmenopausal women who: Have not received hormonal replacement therapy and have vaginal bleeding. Have persistent or unexplained vaginal bleeding after cessation of hormone replacement therapy for 6 weeks. Referral to gynaecology or to a genitourinary medicine clinic should be arranged

2017 NICE Clinical Knowledge Summaries

148. Molluscum contagiosum

transmitted infections. Podophyllotoxin 0.5% is often used to treat anogenital warts and has been demonstrated to be an effective treatment for molluscum contagiosum. The medication is applied by the patient twice a day for 3 consecutive days and can be repeated after a week if necessary. Imiquimod 5% cream has some evidence for its use for anogenital molluscum contagiosum, although it is unlicensed. It is applied to the lesions 3 times a week and washed off 6-10 hours later. Cryotherapy has limited (...) seek medical care. The majority of cases occur in children with the maximum incidence in preschool children aged 1–4 years. Complications from molluscum contagiosum are uncommon but can include scarring, conjunctivitis, keratitis, bacterial superinfection, and psychological distress. Typically, molluscum contagiosum presents with characteristic pinkish or pearly white papules with a central umbilication, which are up to 5 mm in diameter. Lesions appear in clusters in areas anywhere on the body

2017 NICE Clinical Knowledge Summaries

149. Zyclara - imiquimod

Not applicable Information on the reference medicinal product The chosen reference product is: ? Medicinal product which is or has been authorised in accordance with Community provisions in accordance with Community provisions in force for not less than 6/10 years in the EEA: ? Product name, strength, pharmaceutical form: Aldara 5% cream ? Marketing authorisation holder: MEDA AB, Solna, Sweeden ? Date of authorisation: 18/09/1998 ? Marketing authorisation granted by: Community ? Community Marketing (...) . Imiquimod is an immune response modifier. Saturable binding studies suggest that a membrane receptor for imiquimod exists on responding immune cells. Imiquimod has no direct antiviral activity. In animal models imiquimod is effective against viral infections and acts as an antitumour agent principally by induction of alpha interferon and other cytokines. The induction of alpha interferon and other cytokines following imiquimod cream application to genital wart tissue has also been demonstrated

2012 European Medicines Agency - EPARs

150. Homeopathy in the paediatric population

, by virtue of its purported nontoxic nature, appeals to those with legitimate concerns about conventional drugs . Homeopathy is one of the most popular CAM therapies worldwide, especially in Europe . In the United States, its use has increased fivefold since 1990, largely through the sale of over-the-counter products . Homeopathy and homeopathic medicines should not be confused with herbal remedies. Principles of homeopathy A major tenet of homeopathy is the law of similars or ‘like cures like’ (ie (...) deficit hyperactivity disorder Summary Homeopathy is a common form of CAM used to treat paediatric conditions. Based on the available evidence, adverse effects from properly prepared homeopathic medicines seem to be uncommon, although they may be under-reported. However, a major concern is the reluctance on the part of those who practice homeopathy to support vaccinations. As well, delays in seeking conventional medical therapies while waiting for results from homeopathic treatments may jeopardize

2012 Canadian Paediatric Society

151. KHA-CARI adaptation of the KDIGO Guideline for the Care of Kidney Transplant Recipients

. Cross 7 , JM. Eris 1 , D. Goodman 8 , LK. Henderson 9 , MR. Howell 9 , NM. Isbel 3 , J. Kanellis 10,11 , SS. Kotwal 1 , P. Manley 12 , R. Masterson 6 , W. Mulley 10 , KM. Murali 13 , P. O‘Connell 14 , H. Pilmore 12 , B. Pussell 15 , N. Rogers 5 , GR. Russ 5 , RG. Walker 5 , AC. Webster 16 , KJ. Wiggins 6 , G. Wong 9,14,16 , KR. Wyburn 1 1 Transplantation and Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia. 2 Sydney Medical School, University of Sydney, Sydney, Australia. 3 Department (...) Department of Nephrology, Monash Medical Centre , Melbourne, Australia. 11 Department of Medicine, Monash University. Melbourne, Australia. 12 Department Renal Medicine, Auckland City Hospital, New Zealand. 13 Orange Base Hospital, Orange, NSW 14 Centre for Transplant and Renal Research, Westmead Hospital 15 Department of Nephrology, Prince of Wales Hospital, Sydney, Australia 16 School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia. How to cite this guideline. 1

2012 KHA-CARI Guidelines

152. The cost-effectiveness of male HPV vaccination in the United States

, and End Results (SEER) database. The key inputs were the incidence rates for HPV-associated health outcomes, such as cervical intraepithelial neoplasia (CIN), genital warts, juvenile-onset recurrent respiratory papillomatosis, and cervical, vaginal, vulvar, anal, oropharyngeal, and penile cancers. The vaccine efficacy was based on trial data. Vaccination coverage was an important parameter and the data were from the National Immunization Survey. Monetary benefit and utility valuations: The utility (...) was adopted, but only appear to have included the direct medical costs. They stated that patient time and transport costs were not included. Most of the costs were from a published economic evaluation conducted by the authors of this study. Other data were from standard US sources. The costs were treated deterministically, with some values varied in the sensitivity analysis. Details, such as the price year and the discount rate, were reported. Analysis and results: An incremental approach was used

2012 NHS Economic Evaluation Database.

153. An Evaluation of a Customized Insole to Provide Relief From Heel Pain Due to Plantar Fasciitis or General Heel Pain When Used in Footwear Over a Period of Four Weeks

; Subjects with a self-reported history of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications (e.g., azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate mofetil, methotrexate, prednisone, Remicade, Stelara.), and/or radiation as determined by study documentation; Previous assignment to treatment during this study. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you (...) two weeks or are currently participating in a product performance research study or any other type of research, marketing, or product performance study; Subjects who are nursing, pregnant, or planning to become pregnant during the course of the study (self-reported); Subjects who are employed or have family members employed by Market Research/Marketing Consulting, Manufacturing, Distribution, Retail or Marketing of any type of personal care product, drug product, or pharmaceutical; Subjects who

2018 Clinical Trials

154. Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine in HIV and Transplant Patients

risk to the subject. Patient's medication Exclusion criterion only for HIV patients: Subject is receiving or has received in the year prior to enrolment the following immunosuppressive therapies: radiation therapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin, leflunomide (tumour necrosis factor-α antagonists, monoclonal antibody therapies (including rituximab [Rituxan]), intravenous gamma globulin, antilymphocyte sera, or other therapy known to interfere (...) with the immune response. With regard to systemic corticosteroids, a subject will be excluded if she is currently receiving steroid therapy, has recently (defined as within 2 weeks of enrolment) received such therapy, or has received 2 or more courses of high dose corticosteroids (≥20mg/day of prednisone [or equivalent] orally or parenterally) lasting at least 1 week in duration in the year prior to enrolment. Subjects using inhaled, nasal, or topical corticosteroids are considered eligible for the study

2018 Clinical Trials

155. Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

or subcutaneous immunoglobulin supplementation, radiation therapy, or immunomodulatory treatment within the previous 6 months (presence of precancerous lesions is not exclusionary Receipt of an investigational vaccine within 2 weeks of day 0. Receipt of ACIP recommended immunizations within 1 week of day 0. Any condition that, in the opinion of the investigator, contraindicates participation in this study. Contacts and Locations Go to Information from the National Library of Medicine To learn more about (...) , the immunogenicity of vaccines and in particular HPV preventive vaccines has never been systematically studied in patients with ICL. This will be a phase 2, open-label study to assess the immunogenicity of the U.S. Food and Drug Administration (FDA)-approved 9-valent HPV recombinant vaccine GARDASIL 9 in patients 18- through 60-years-old with ICL, irrespective of HPV serostatus, presence of HPV-associated diseases, or previous immunization with bivalent or quadrivalent HPV vaccine, as well as healthy controls

2018 Clinical Trials

156. Immunogenicity From 1 Dose of Bivalent HPV Vaccine in Girls to 3 Doses of Quadrivalent Vaccine in Women: the PRIMAVERA-ESCUDDO Trial

antibody levels measured at 24 and/or 36 months [ Time Frame: Assessed at 36 months after initial vaccination, withinterim analysis at 24 months ] Comparison of immune response for 1-dose of the bivalent vaccine Cervarix in girls 9-14 years old to immune response for 3-doses of the quadrivalent vaccine Gardasil in women 18-25 Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family (...) impediment to preventing this often-fatal cancer. The goal of this research is to provide convincing and actionable evidence for regulatory bodies that a single dose of the HPV vaccine will elicit an immune response sufficient to protect against targeted HPV infections and subsequent neoplasms. This study will provide earlier and complementary results to the definitive 24,000-girl study evaluating the vaccine efficacy for a 1-dose regimen against virologic outcomes, which is underway in Costa Rica

2018 Clinical Trials

157. Evaluating the Safety and Pharmacokinetics of VRC-HIVMAB075-00-AB (VRC07-523LS) in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants

PSRT will determine eligibility on a case-by-case basis. Previous receipt of humanized or human monoclonal antibodies (mAbs), whether licensed or investigational; the HVTN 128 PSRT will determine eligibility on a case-by-case basis. Previous receipt of monoclonal antibodies against HIV Immune System Immunosuppressive medications received within 30 days before first infusion (Not exclusionary: [1] corticosteroid nasal spray; [2] inhaled corticosteroids; [3] topical corticosteroids for mild (...) examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health. A clinically significant condition or process includes but is not limited to: A process that would affect the immune response, A process that would require medication that affects the immune response, Any contraindication to repeated infusions or blood draws, including inability to establish venous access, A condition that requires active medical

2018 Clinical Trials

158. Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults

provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Sequence A: Dapivirine gel Participants will receive 2.5 g of dapivirine gel administered rectally via an applicator, followed by a 2- to 4-week washout period. Participants will then receive a second dose of up to 10 g of dapivirine gel administered rectally via a coital simulation device. Drug: Dapivirine gel Dapivirine gel (0.05%); administered rectally Experimental (...) ) or designee At Screening, history of consensual receptive anal intercourse (RAI) at least once in the past year per participant report Willing not to take part in other research studies involving drugs, medical devices, genital or rectal products, or vaccines for the duration of study participation (including the time between Screening and Enrollment) Willing to abstain from RAI, receptive oral anal stimulation (i.e., rimming), rectal stimulation via fingers, as well as the insertion of any non-study

2018 Clinical Trials

159. Physiopathologic Aspects and Quality of Life in Participants With Eye Dark Circles

Questionnaire on Dark Circles, Medical History, and Lifestyle Habits [ Time Frame: Day 1 ] The Subject Questionnaire on Dark Circles, Medical History and Lifestyle Habits is a 15-item questionnaire completed by the participant. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor (...) to the study visit appointment Willingness to cleanse the face and remove all makeup at least 15 minutes prior to each scheduled clinic visit Willingness to have facial exams, skin instrumentation measurements, and digital photos performed on the face. Exclusion Criteria: Individuals with active symptoms of allergy, cold sore or warts, active psoriasis or eczema, rosacea, sunburn, open wounds, neurotic excoriations, excessive scarring, tattoos, or other skin conditions in the test area Uncontrolled disease

2018 Clinical Trials

160. Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults

involving drugs, medical devices, genital or rectal products, or vaccines for the duration of study participation (including the time between Screening and Enrollment) Willing to follow abstinence requirements for the duration of study participation (See the protocol for additional information) For participants of childbearing potential: a negative pregnancy test at Screening and Enrollment For participants of childbearing potential: Per participant report at Enrollment, using an effective method (...) months prior to Enrollment Non-therapeutic injection drug use in the 12 months prior to Enrollment Participation in research studies involving drugs, medical devices, genital or rectal products, or vaccines within 30 days of the Enrollment Visit Gynecologic, genital, or rectal procedure (e.g., tubal ligation, dilation and curettage, piercing, hemorrhoidal resection, polyp removal) 60 days or less prior to Enrollment, or rectal biopsy, 7 days or less prior to Enrollment. Note: Colposcopy and cervical

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>